A project coordinated by VTT turns plant cells into medical factories
Plants generate valuable secondary metabolic compounds, which can be used as pharmaceuticals. Most of these compounds are so complex that their chemical synthesis is not economically feasible. This is why biotechnology opens up a whole new avenue of possibilities. The SmartCell project will focus on terpene compounds, which are valuable for the pharmaceutical industry. These compounds for example are used in the treatment of cancer and malaria. The expertise and technology created during the project can be applied to a considerable extent in developing the biotechnological production of other compound groups in plants and plant cells.
The SmartCell project brings together research partners from fourteen leading European research institutes and universities as well as three small and medium-sized and two major industrial enterprises. In addition to VTT, the project participants include e.g. VIB (Belgium), Leiden University (the Netherlands), Lleida University (Spain) and Fraunhofer IME Aachen, (Germany). The project’s total budget is EUR 8.5 million, of which the EU’s contribution is EUR 6 million. The contractual negotiations will soon be concluded, and the project will start in January 2009.
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.